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Objective: To clarify the impact of thymidine phosphorylase (TPase) expression in 
patients with urothelial carcinoma of the urinary bladder (UB-UC), we investigated 
the expression profiles of TPase and its role in the clinical behavior of UB-UC in 
patients with this disease.
Materials and Methods: A total of 32 patients with UB-UC were enrolled in this 
study. The expression intensity and pattern of TPase were examined by immunohis-
tochemical analysis. The results were correlated with clinicopathological parameters.
Results: Tumor cells were significantly immunoreactive to TPase staining, but showed 
stronger staining in adjacent non-tumorous stromal tissues. The staining intensity 
and patterns were correlated with the stage (p = 0.032, p = 0.010, respectively).
Conclusions: Both the intensity and pattern of expression of TPase were associated 
with tumor stage in UB-UC in this cohort. There were also high expression levels of 
TPase in most bladder cancer cells and adjacent stromal tissues. These findings sug-
gest that tumor and stromal TPase expressions may cooperatively promote tumor 
progression and angiogenesis.
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1.  Introduction
Urothelial carcinoma of the urinary bladder (UB-UC) is 
the fourth most common cancer in men and the tenth 
most common one in women in the US, accounting for 
an estimated 6% and 2% of new cases, respectively.1 
Because of long-term consumption of groundwater con-
taminated by arsenic in some parts of southern Taiwan 
several decades previously, UB-UC is also an important 
cause of cancer deaths in Taiwan accounting for 3.42% 
of all cancer deaths in men and 1.59% in women.2 
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Similar to Western countries, the incidence rate and 
mortality rate in Taiwan are increasing at a stable pace. 
Determining how to predict biological behaviors of blad-
der cancers is a critical contemporary clinical issue.
It is well known that angiogenesis plays important roles 
in tumorigenesis and invasiveness. Several angiogenic fac-
tors are involved in the process of tumor angiogenesis. 
Thymidine phosphorylase/platelet-derived endothelial cell 
growth factor (TPase/PD-ECGF) is implicated in the pro-
cess of angiogenesis. Recently, several study groups dem-
onstrated that the expression patterns of TPase were 
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associated with clinical outcomes and therapeutic re-
sponses in several cancer types, including lung cancer 
and breast cancer.3–10 However, it is not well understood 
whether TPase also plays an important role in clinical 
outcomes and therapeutic responses in patients with 
UB-UC. Previous studies on the possible role of TPase in 
patients with UB-UC are conflicting, which may be due 
to different methodologies and methods of sample col-
lection.11–18 To clarify the impact of TPase expression in 
patients with UB-UC in Taiwan, we investigated the 
expression patterns of TPase and its role in the clinical 
behavior of UB-UC in patients with this disease.
2.  Materials and Methods
2.1.  Patients and tumor samples
All studies were performed after approval and institute 
oversight of the Institutional Review Board for the 
Protection of Human Subjects at E-Da Hospital. Written 
informed consent was obtained from each patient or 
their family, as appropriate. All 47 consecutive patients 
admitted to our institution for treatment of bladder can-
cer by partial/radical cystectomy and bilateral lymph-
adenectomy during the period from October 2004 to 
September 2007 were potential candidates for these 
analyses. Of these 47 patients, adequate archival tissues 
were only available in 32 patients for immunohisto-
chemical analysis. Among these 32 patients, 23 patients 
underwent a radical cystectomy, seven underwent a 
partial cystectomy, and two patients underwent transure-
thral resection of the bladder tumor. Tumors were graded 
according to the World Health Organization 2004 grad-
ing criteria and staged according to the American Joint 
Committee on Cancer staging system 2002. The clinical 
data were retrospectively collected by chart review, and 
the length of follow-up was calculated from the date of 
surgery. Disease recurrence was defined as any evidence 
of a tumor in a retained urinary bladder or previous sur-
gical site. When patients died, the cause of death was 
determined by the treating physicians, by chart review 
corroborated by the death certificate, or by the death 
certificate alone. Perioperative mortality (death within 
30 days of surgery) was censored at the time of death for 
the bladder cancer-specific survival analyses. Patients 
were generally followed-up postoperatively at least 
every 3 months for the first 2 years, semiannually for the 
3rd and 4th years, and annually thereafter. Follow-up 
visits generally consisted of a physical examination and 
serum chemistry evaluation, along with liver function 
tests and alkaline phosphorylase when clinically indi-
cated. Diagnostic imaging of the upper urinary tract 
such as ultrasonography and/or intravenous urography 
and chest radiography were performed at least annually 
or when clinically indicated. A bone scan and/or computed 
tomography were performed at the discretion of the 
treating physician. The median follow-up was 19.94 months 
(range, 2–50).
2.2.  Immunohistochemical staining
Tissue samples in paraffin blocks were sectioned into 
4 μm slices and placed on glass slides. After deparaffini-
zation and blocking of endogenous peroxidase activity, 
sections were placed in 0.1 mol/L citrate buffer (pH 6.0) 
and heated in a microwave oven for 10 minutes. After 
being washed with phosphate-buffered saline (PBS) four 
times, sections were treated with horse normal serum 
in PBS (1:10) at room temperature for 40 minutes and 
incubated with primary anti-TPase monoclonal antibody 
(MoAb 654-1) (P-GE.44C; Calbiochem, San Diego, CA, USA) 
diluted in PBS (1:500) overnight at 4°C. After another 
washing with PBS, sections were further incubated with 
secondary biotinylated antimouse IgG (Vectarstain ABC 
kit; Vector Laboratories, INC., Burlingame, CA, USA) for 
40 minutes at room temperature. After being washed 
again with PBS, sections were incubated with avidin-
biotin complex (Vectastain ABC Kit; Vector Laboratories) 
for 40 minutes at room temperature and developed with 
1 mg/mL 3,3-diaminobenzidine tetrahydrochloride in 
Tris-HCl buffer (pH 7.6) containing 0.03% hydrogen per-
oxide. Sections were also counterstained with hematox-
ylin and mounted. For staining detection, the Dako REAL 
EnVision Detection System (Dako, Hamburg, Germany) 
was used according to the manufacturer’s recommen-
dations. In each experiment, a negative control was in-
cluded in which non-immune antiserum was used instead 
of the primary antibody.
We obtained the mean, maximum, range, and stan-
dard deviation of the staining intensity, and the percent 
positive area measurements using 10 random hot spots 
within each specimen as judged by two or three obser-
vers (VCL, KL, and CTH) through an open discussion. The 
mean of duplicate scores was calculated for data analy-
sis. The intensity scores of immunohistochemical stain-
ing were graded from 0 to 3 (0, no staining; 1, weak 
staining; 2, strong staining; 3, very strong staining). The 
pattern scores of immunohistochemical staining ranged 
from 0–4 (0, no staining; 1, 0–10% positive; 2, 10–25% 
positive; 3, 25–50% positive; and 4, > 50% positive). Inten-
sity scores of 0 and 1 were considered slightly immuno-
reactive, and those of 2 and 3 were considered highly 
immunoreactive. Pattern scores of 0, 1, and 2 were con-
sidered focal expression, and those of 3 and 4 were 
considered diffuse expression.
2.3.  Statistical analysis
Continuous data in the two groups were evaluated by 
Mann-Whitney U-tests to compare the means. Cate-
gorical data were analyzed using the chi-squared test with 
Fisher’s exact probability test, as appropriate. A p value 
of < 0.05 was considered statistically significant. Group 
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data are presented as the mean ± standard deviation, 
number, or percentage. The statistics program used for 
the analysis was SPSS 13.0 (SPSS, Chicago, IL, USA) for 
Windows.
3.  Results
3.1.  Patient characteristics
Clinical and demographic characteristics of the patients 
in this study are shown in Table 1. Our study cohort con-
sisted of 21 men and 11 women with a median age of 
65.9 years (range, 42–83 years). Most patients with a 
high-grade tumor were younger than 65 years. All ex-
cept four patients lived and patients were progression-
free during the follow-up period. Among these four 
patients, two died of non-cancerous causes. One patient 
developed pneumonia with septic shock after adjuvant 
chemotherapy, and the other died of respiratory failure 
due to a chronic obstructive pulmonary disorder with 
acute exacerbation. The mean follow-up time was 19.9 
months (range, 2–50 months).
3.2.  Expression of TPase
The anti-TPase antibodies significantly stained the cyto-
plasm and some nuclei of tumor cells, and stronger 
staining was also observed in adjacent non-tumorous 
stromal tissues. The percentage of nuclear staining in 
advanced stages (T2–T4) was higher than that in low 
stages (Ta–T1) (40% vs. 14.3%). The intensities and pat-
terns of immunohistochemical staining were arbitrarily 
scored, and 65.6% of UB-UC specimens showed a mod-
erate reaction and 40.6% showed a strong reaction. The 
staining intensity and patterns were correlated with the 
stage (p = 0.068 and p = 0.019, respectively). There were no 
statistically significant correlations between the degree 
of TPase expression and other tumor variables (Tables 2 
and 3). In addition, adjacent urothelial cells and distant 
stromal tissues were negatively or weakly stained by 
anti-TPase antibodies, compared with strongly stained 
tumor cells and neighboring stromal tissues. However, 
when evaluating the postoperative recurrence after ex-
cluding the T1 subpopulation, the expression of TPase 
activity was correlated with disease recurrence (inten-
sity, p = 0.027; pattern, p = 0.067). The percentage of nu-
clear staining was higher in advanced stages (T2–T4) than 
that in low stages (Ta–T1) and normal tissues (p = 0.150). 
Lymphovascular invasion also seems to be higher in ad-
vanced stages, however no statistical significance can be 
demonstrated (p = 0.069) (Figure 1).
4.  Discussion
With recent advances in molecular biology and biotech-
nology, a plethora of biomarkers and therapeutic targets 
for cancer treatment are being explored and identified. 
Ongoing research into the molecular biology underlying 
tumorigenesis has enabled the development and clinical 
application of novel therapies that target key compo-
nents of signaling pathways mediating angiogenesis, a 
process integral to tumor growth and metastasis. Among 
angiogenic factors implicated in angiogenesis, TPase/
PD-ECGF is a well-known, potent angiogenic molecule, 
which induces endothelial cell migration and proliferation, 
and is also a unique enzyme involved in 5-flourouracil 
(5-FU) metabolism. TPase/PD-ECGF is also a biomarker 
that predicts tumor response to 5-FU-based therapy. 
The expression of TPase in several types of malignant 
tumors is associated with increased angiogenesis, aggres-
siveness, and a poor prognosis.3–10
O’Brien et al. characterized the expression of TPase 
in 105 primary bladder cancer patients treated by trans-
urethral resection, and they found that its expression was 
significantly upregulated in bladder tumors compared 
with that in normal bladder tissues.15 However, only the 
tumor grade correlated with the expression of TPase in 
their report. Tanaka et al also reported no correlation 
between the expression of TPase and the number of 
Table 1  Patient demographics and clinicopathological 
characteristics
 n
Sex
 Male 21
 Female 11
Median age (yr)
 Male 67.9 (42–83)
 Female 61.1 (50–79)
Follow-up period (mo) 19.9 (2–50)
Grade 
 Low  4
 High 28
Lymphovascular invasion
 Yes 12
 No 15
 ND  5
pT category
 pTa  1
 pT1  6
 pTis  0
 pT2 (2a/2b) 9 (7/2)
 pT3 (3a/3b) 14 (11/3)
 pT4 (4a/4b) 2 (1/1)
pN category
 pN0 16
 > pN1  4
 pNx 12
Data presented as median (range) or n. ND = not determined.
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Table 2  Relationship between thymidine phosphorylase (TPase) expression intensity in bladder cancer and clinicopathological 
characteristics*
  High TPase (n = 21) Low TPase (n = 11)
Characteristics Total no.
 n (%) n (%) 
p
Total no. stained 64 42 (68) 22 (32) 
Sex     0.442
 Male  42 29 (45) 13 (20) 
 Female 22 13 (20) 9 (15) 
Grade     0.106
 Low   8 2 (3) 6 (9) 
 High 56 40 (63) 16 (25) 
Lymphovascular invasion    0.239
 Yes 24 18 (33) 6 (11) 
 No 30 14 (26) 16 (30) 
 ND 10 10  0  
pT category    0.032
 pTa–T1 14 4 (6) 10 (16) 
 pT2–4 50 40 (62) 10 (16) 
*Data presented as n or n (%). TPase staining was performed twice in each patient. Staining intensity scores of 0 and 1 are defined as low intensity, 
while staining intensity scores of 2 and 3 are defined as high intensity. ND = not detected.
Table 3  Relationship between thymidine phosphorylase (TPase) expression patterns in bladder cancer and clinicopathological 
characteristics*
  Diffuse TPase (n = 13) Focal TPase (n = 19)
Characteristics Total no.
 n (%) n (%) 
p 
Total no. stained 64 26 (41) 38 (59)
Sex    0.712
 Male  42 18 (28) 24 (38)
 Female 22 8 (12) 14 (22)
Grade    0.613
 Low   8 2 (3) 6 (9)
 High 56 24 (38) 32 (50)
Lymphovascular invasion    0.570
 Yes 24 14 (33) 10 (11)
 No 30 6 (26) 24 (30)
 ND 10 8  2
pT category    0.010
 pTa–T1 14 4 (6) 10 (16)
 pT2–4 50 40 (62) 10 (16)
*Data presented as n or n (%). A TPase staining pattern score of < 25% was defined as focal, whereas that of > 25% was defined as diffuse. 
ND = not detected.
tumors, tumor configuration, lymph node involvement, 
venous invasion, or overall survival.18 Furthermore, they 
detected no significant serum level of TPase in any pa-
tient. In contrast to the results from Tanaka et al., Arima 
et al. demonstrated significant correlations between TPase 
expression and histological grade, the infiltration pat-
tern, local invasion, and lymph node metastasis.11 They 
concluded that TPase overexpression is an independent 
prognostic factor, and TPase activity and its level of ex-
pression influences the progression of UC and the prog-
nosis of bladder cancer. Subsequent studies showed that 
the expression of TPase is correlated with the recurrence-
free rate among superficial bladder tumors.13–17
In our study, we found that TPase was not only ex-
pressed in tumor cells but was also highly expressed in 
stromal cells adjacent to bladder cancer. In addition, the 
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Figure 1 Immunohistochemical expression of thymidine phosphorylase (TPase) in urothelial cancer of the urinary bladder. 
(A) Absent to weak expression of TPase in normal urothelial cells (original magnification, 400×). (B) Strong expression of TPase in 
urothelial cancer cells (400×). (C) Strong TPase immunoreactivity in the infiltrating front of tumors (black arrow) and in areas of 
necrosis (white arrow, 100×). (D) Nuclear staining of TPase, as indicated by the white arrow (400×).
infiltrating front of tumors and areas of necrosis were 
immunoreactive to TPase as evidenced by strong stain-
ing. Tanaka et al. and Sivridis et al. reported prominent 
TPase expression at the invading tumor periphery (inva-
sive front) in endometrial cancer, and these findings 
highlight the importance of this area where tumor ang-
iogenesis is most active.19,20 This unique phenomenon 
may explain how angiogenic factors are released in this 
area and thereby promote subsequent angiogenesis.19,20 
Our findings suggest that TPase may play an important 
role in modulating angiogenesis in the microenviron-
ment between the tumor and host tissues.
On the other hand, TPase immunoreactivity in tumor 
cells is heterogeneous, in both nuclear and cytoplasmic 
components in some cases, whereas in other tumors, 
the immunoreactivity is almost completely confined to 
the cytoplasm. In our study, we found that the percent-
age of nuclear staining was higher in advanced stages 
(T2–T4) than that in low stages (Ta–T1) and normal tis-
sues (40% vs. 14.3%). Future studies need to investigate 
the role of nuclear TPase in tumor progression.
We showed no correlation between TPase expression 
of tumor cells and other tumor variables in our Taiwanese 
patients compared with findings in previous unpublished 
data. There were also no correlations between TPase ex-
pression and other established prognostic parameters in 
bladder cancer except for tumor stage. Nevertheless, high 
expression levels of TPase were observed in most bladder 
cancers and neighboring stromal tissues. These findings 
may provide valuable information for managing bladder 
cancer. Tumor tissues and also normal tissues abutting 
bladder cancer have the potential for angiogenesis for 
tumor development. In addition, a number of thymidine 
analogues are metabolized by TPase. Capecitabine, a pro-
drug of 5-FU, is converted to 5-FU by TPase. Differ ent 
expression profiles of TPase in bladder cancers may indi-
cate that capecitabine might be differently activated in 
tumor tissues. Tumors in which TPase activity is overex-
pressed could degrade salvaged thymidine and might be 
more sensitive to thymidylate synthase inhibition.15 There-
fore, detection of TPase expression patterns might indi-
cate the likely response to 5-FU or thymidylate synthase 
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inhibition such as with methotrexate-based chemother-
apies. Further investigations are necessary to determine 
the role of TPase in chemotherapeutic responses.21
Our study has some limitations. First, the numbers in 
our cohort were limited. Second, our study was retro-
spective; therefore, some clinicopathological parameters 
were not adequately recorded or analyzed. A prospec-
tive large cohort study needs to be designed to deduce 
the actual role of TPase in human bladder cancer.
5.  Conclusions
The expression of TPase was only associated with tumor 
stage in our Taiwanese patients. In addition, there were 
high expression levels of TPase in most bladder cancers 
and adjacent stromal tissues. These findings suggest 
that tumor and stromal TPase expression may coopera-
tively promote tumor progression and angiogenesis.
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